| JAK2 |
Homo sapiens |
|
JAK2 is differentially expressed in 115 experiments [111 up/113 dn]: 26 organism parts: lung [1 up/1 dn], primary gastric tumor [1 up/0 dn], ...; 26 disease states: normal [2 up/8 dn], breast carcinoma [2 up/0 dn], ...; 23 cell types, 26 cell lines, 31 compound treatments and 17 other conditions. |
| JAK2 |
|
jak2a (Danio rerio)
JAK2_RAT (Rattus norvegicus)
Jak2 (Mus musculus)
jak2b (Danio rerio)
(Compare orthologs)
|
|
|
| Band 4.1 domain, FERM domain, Protein kinase, ATP binding site, Protein kinase-like domain, Tyrosine-protein kinase |
|
|
| Budd-Chiari syndrome, Leukemia, acute myelogenous, Myelofibrosis, idiopathic, Polycythemia vera, Thrombocythemia, essential |
|
|
| ATP binding, G-protein coupled receptor protein signaling pathway, JAK-STAT cascade involved in growth hormone signaling pathway, SH2 domain binding, acetylcholine receptor binding |
|
|
|
O60674
Q506Q0
Q52R86
Q8IXP2
|
|
|
|
ENSG00000096968
|
|
|
| Factor Value |
Factor |
Up/Down |
Legend: - number of studies the gene is up/down in
|
|
Normal
|
Disease state |
|
|
None
|
Compound treatment |
|
|
Homo sapiens
|
Organism |
|
|
Pan troglodytes
|
Organism |
|
|
Control
|
Compound treatment |
|
|
Breast carcinoma
|
Disease state |
|
|
Not applicable
|
Histology |
|
|
N/a
|
Test result |
|
|
FLAP
|
Compound treatment |
|
|
MDA-MB-231
|
Cell line |
|
|
MK886
|
Compound treatment |
|
|
Chronic lymphocytic leukemia
|
Disease state |
|
|
Invasive ductal carcinoma
|
Histology |
|
|
BT-474
|
Cell line |
|
|
Cystic change
|
Histology |
|
|
Interferon-gamma
|
Compound treatment |
|
|
Estrogen receptor 1 negative; ...
|
Test result |
|
|
0 cm away from the tumor bound...
|
Observation |
|
|
Stromal cell
|
Cell type |
|
|
Macrophage
|
Cell type |
|
|
Dendritic cell
|
Cell type |
|
|
HNRPA2B
|
Compound treatment |
|
|
Lung
|
Organism part |
|
|
SW480
|
Cell line |
|
|
SW620
|
Cell line |
|
|
Bacterial endotoxin
|
Compound treatment |
|
|
Primary gastric tumor
|
Organism part |
|
|
BT474
|
Cell line |
|
|
MDA468
|
Cell line |
|
|
Lipopolysaccharide
|
Compound treatment |
|
|
Tumor
|
Organism part |
|
|
Experimental malaria-infected
|
Disease state |
|
|
Glucocorticoid sensitive
|
Phenotype |
|
|
Granulocyte
|
Cell type |
|
|
Caudate nucleus
|
Organism part |
|
|
Pretreatment primary sample
|
Clinical info |
|
|
Vascular smooth muscle cell
|
Cell type |
|
|
Chondrocyte
|
Cell type |
|
|
Spermatocyte
|
Cell type |
|
|
MCF-7
|
Cell line |
|
|
M1 macrophage
|
Cell type |
|
|
Acute promyelocytic leukemia
|
Disease state |
|
|
U937
|
Cell line |
|
|
Interferon-gamma + lipopolysac...
|
Compound treatment |
|
|
MCF10A
|
Cell line |
|
|
SKBR3
|
Cell line |
|
|
T47D
|
Cell line |
|
|
Clear cell sarcoma of the kidn...
|
Disease state |
|
|
Wilms' tumor
|
Disease state |
|
|
Huntington's disease
|
Disease state |
|
|
Infergen + interferon-gamma
|
Compound treatment |
|
|
M-CSF
|
Compound treatment |
|
|
Idiopathic dilated cardiomyopa...
|
Disease state |
|
|
Fetal bovine serum in media
|
Growth condition |
|
|
Monocyte
|
Cell type |
|
|
Respiratory syncytial virus
|
Infection |
|
|
CodeLink Labeling
|
Protocol type |
|
|
Testis
|
Organism part |
|
|
Cerebellum
|
Organism part |
|
|
Organism_part
|
Material type |
|
|
Cell
|
Material type |
|
|
Normal
|
Disease staging |
|
|
Infergen
|
Compound treatment |
|
|
Lung adenocarcinoma
|
Disease state |
|
|
Methotrexate
|
Compound treatment |
|
|
HL-60
|
Cell line |
|
|
Vanadium pentoxide
|
Compound treatment |
|
|
Superficial transitional cell ...
|
Disease state |
|
|
Hydrogen peroxide
|
Compound treatment |
|
|
Seminiferous tubule
|
Organism part |
|
|
Skeletal muscle
|
Organism part |
|
|
Cartilage
|
Organism part |
|
|
Trichostatin A
|
Compound treatment |
|
|
Thymus
|
Organism part |
|
|
Atrial mycocardium
|
Organism part |
|
|
Ventricular myocardium
|
Organism part |
|
|
SkinEthic keratinocyte
|
Cell type |
|
|
Epidermal keratinocyte
|
Cell type |
|
|
Serum starvation + thymidine b...
|
Growth condition |
|
|
Plasma cell
|
Cell type |
|
|
B lymphocyte
|
Cell type |
|
|
Cigarette smoke
|
Growth condition |
|
|
Incubator control
|
Growth condition |
|
|
Waldenstrom's macroglobulinemi...
|
Disease state |
|
|
Symptomatic
|
Disease staging |
|
|
U87
|
Cell line |
|
|
U373
|
Cell line |
|
|
T47-D
|
Cell line |
|
|
Filtered air
|
Compound treatment |
|
|
Monocyte at intermediate diffe...
|
Cell type |
|
|
Synovial fluid
|
Organism part |
|
|
Peripheral blood
|
Organism part |
|
|
HaCaT
|
Cell line |
|
|
Pseudomonas aeruginosa
|
Infection |
|
|
Unknown_sex
|
Sex |
|
|
IgV status unknown
|
Genotype |
|
|
Macaca mulatta
|
Organism |
|
|
Frontal cortex, superior motor...
|
Organism part |
|
|
SKMEL5
|
Cell line |
|
|
5-aza-2'-deoxycytidine
|
Compound treatment |
|
|
Fisetin
|
Compound treatment |
|
|
SsMCF7
|
Cell line |
|
|
Granulocyte macrophage-colony ...
|
Compound treatment |
|
|
HeLa
|
Cell line |
|
|
Erythrocyte
|
Cell type |
|
|
Control - IL-1b
|
Compound treatment |
|
|
Peripheral blood mononuclear c...
|
Cell type |
|
|
T cell
|
Cell type |
|
|
Oligodendroglioma
|
Disease state |
|
|
Gastric cancer
|
Disease state |
|
|
KSHV-negative EBV-positive
|
Clinical info |
|
|
Benign nevi
|
Disease state |
|
|
BL41K3
|
Cell line |
|
|
BJABK3
|
Cell line |
|
|
Baseline uninfected
|
Disease state |
|
|
ITM-E6E7-ST
|
Cell line |
|
|
Multiple myeloma
|
Disease state |
|
|
Central memory 1 CD4 T cell
|
Target cell type |
|
|
Control - interferon-gamma
|
Compound treatment |
|
|
Granulocyte-colony stimulating...
|
Compound treatment |
|
|
Aortic stenosis
|
Disease state |
|
|
Actinomycin D
|
Compound treatment |
|
|
Control - untreated
|
Compound treatment |
|
|
Temporal lobe
|
Organism part |
|
|
Spermatid
|
Cell type |
|
|
HTERT/HPVE6/HPVE7/SV40t transf...
|
Gene modification |
|
|
HTERT/HPVE6 transfection
|
Gene modification |
|
|
Bladder carcinoma
|
Disease state |
|
|
Enzo Labeling
|
Protocol type |
|
|
Senescence bypassed
|
Phenotype |
|
|
Affymetrix Labeling
|
Protocol type |
|
|
Postprandial lipid micelles in...
|
Growth condition |
|
|
PC3
|
Cell line |
|
|
Control for heregulin
|
Compound treatment |
|
|
Rapamycin
|
Compound treatment |
|
|
Smooth muscle
|
Organism part |
|
|
BDCA1+ dendritic cell
|
Cell type |
|
|
HPL1
|
Cell line |
|
|
Glucocorticoid resistant
|
Phenotype |
|
|
Grade IV
|
Tumor grading |
|
|
KSHV-positive EBV-negative
|
Clinical info |
|
|
Adult
|
Developmental stage |
|
|
Infant
|
Developmental stage |
|
|
Estrogen receptor 1 negative; ...
|
Test result |
|
|
Chronic myelogenous leukemia
|
Disease state |
|
|
ERalpha transfected
|
Genotype |
|
|
ERbeta transfected
|
Genotype |
|
|
STK3 overexpression
|
Genotype |
|
|
Lymphoid tissue
|
Organism part |
|
|
Bone marrow
|
Organism part |
|
|
Frontal cortex, primary motor ...
|
Organism part |
|
|
Epidermal growth factor
|
Compound treatment |
|
|
Female
|
Sex |
|
|
Lymphatic endothelial cell
|
Cell type |
|
|
ITM-ST
|
Cell line |
|
|
Basal cell
|
Cell type |
|
|
T-cell lymphoblastic lymphoma
|
Disease state |
|
|
Atrioventricular node
|
Organism part |
|
|
Dorsal root ganglion
|
Organism part |
|
|
Non-ischemic cardiomyopathy
|
Disease state |
|
|
5-aza-2'-deoxycytidine + trich...
|
Compound treatment |
|
|
Serum starvation synchronizati...
|
Growth condition |
|
|
ITS medium
|
Growth condition |
|
|
Inter-prandial lipid micelles ...
|
Growth condition |
|
|
ITS medium with albumin-bound ...
|
Growth condition |
|
|
Poorly differentiated gastric ...
|
Disease state |
|
|
G1
|
Tumor grading |
|
|
Acute rejection
|
Clinical info |
|
|
CD3int CD4+ CD8+
|
Phenotype |
|
|
Double positive thymocyte
|
Cell type |
|
|
Jurkat
|
Cell line |
|
|
Stage IIIc/2
|
Disease staging |
|
|
MDS-associated acute myeloid l...
|
Disease state |
|
|
Acute myeloid leukemia
|
Disease state |
|
|
Parietal lobe
|
Organism part |
|
|
CD8+ naive CD8 T cell
|
Cell type |
|
|
Pancreas
|
Organism part |
|
|
Astrocytoma
|
Disease state |
|
|
Subthalamic nucleus
|
Organism part |
|
|
Stage II
|
Disease staging |
|
|
IgV unmutated
|
Genotype |
|
|
Cingulate cortex
|
Organism part |
|
|
Cigarette smoke
|
Compound treatment |
|
|
Interferon alpha
|
Compound treatment |
|
|
|
|
|
Processing time: 0.139 secs.